|Day Low/High||112.97 / 113.40|
|52 Wk Low/High||34.53 / 114.20|
Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a "perilous reversal" (up big yesterday but down big today) candidate
Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a strong on high relative volume candidate
Here are Friday's top research calls, including upgrades for Chevron, Hertz and Kohl's, and a downgrade for Blackstone.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGNC, AU, CKP, CMCT, CPLA, HURC, KSS, MTW, PH, PRTS, SAIC, UAN, ZOES Downgrades: DPLO, GNE, MRVC, VISI Initiations: ONCE Read on to get TheStreet Quant Ratings' detailed report:
Spark Adds New Program for One of the Leading Causes of Inherited Retinal Disease, Broadening Its Pipeline of Potential Treatments for Rare Blinding Conditions
Investors considering a purchase of Spark Therapeutics Inc shares, but tentative about paying the going market price of $23.99/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $20 strike, which has a bid at the time of this writing of $3.50.
While the world's attention turns to Pennsylvania on February 2 nd for Groundhog Day prognostications about continuing winter weather, investment professionals will gather in Philadelphia on February 3 rd for the 2016...
Join Emerald Asset Management for the 23 rd annual Groundhog Day Investment Forum on February 3 rd in Philadelphia.
My biotech and pharma superlatives for 2015.
The Children's Hospital of Philadelphia Foundation to be a Selling Stockholder
Presentation Highlights Positive Trend in Visual Acuity, Together With Highly Statistically Significant Positive Results in Primary and First Two Secondary Efficacy Endpoints
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.